HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Kala Pharmaceuticals (NASDAQ:KALA) but has reduced the price target from $24 to $22.
November 17, 2023 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kala Pharmaceuticals maintains a Buy rating from HC Wainwright & Co., although the price target has been lowered from $24 to $22.
While the reduction in price target could be seen as a negative signal, the maintenance of a Buy rating suggests that the analyst still sees positive potential in KALA's stock. The impact is likely to be neutral to slightly negative in the short term as the market digests the mixed signals of a lower price target with a maintained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100